Studies presented at this month’s American Heart Association meeting in Atlanta suggest that heart scans conducted with Cardiolite, a myocardial perfusion agent from North Billerica, MA-based Du Pont, may help clinicians predict a patient’s
Studies presented at this months American Heart Association meeting in Atlanta suggest that heart scans conducted with Cardiolite, a myocardial perfusion agent from North Billerica, MA-based Du Pont, may help clinicians predict a patients risk of future cardiac events and avoid performing invasive procedures. Researchers at Cedars Sinai Medical Center used Cardiolite in SPECT scans on 2600 patients to evaluate whether assessing cardiac function and perfusion would help predict the likelihood of both fatal and nonfatal heart attacks. The team found that cardiac functionthe blood volume passing through the heartis a strong cardiac death indicator, while perfusionblood flow to the heart tissueis a strong nonfatal heart attack risk indicator. The group surmised that evaluating these two factors could increase physicians accuracy in assessing a patients future heart attack risk.
In another study, conducted at the Medical College of Virginia, researchers used Cardiolite in the emergency room to assess whether patients with chest pain required coronary angiography. The 1000-patient study showed that fewer patients required the procedure when Cardiolite was used to appraise their condition. In a related study at MCV, 600 patients with chest pain but at low risk for heart attack were assessed with a Cardiolite scan, allowing clinicians to evaluate the extent of heart damage without more invasive testing.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.